Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc. (n.d.). Retrieved 1 December 2020, from https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy/
2 Matching Annotations
- Dec 2020
-
investors.modernatx.com investors.modernatx.com
Tags
- is:webpage
- analysis
- biotechnology
- phase 3
- lang:en
- COVID-19
- study
- vaccine
- safety
- Moderna
- vaccine efficacy
- patient
Annotators
URL
-
- Nov 2018
-
www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
-
Experts suggest family engagement in care can improve safety for hospitalizedchildren
Connection between family engagement in care and safety
-